摘要
目的本研究对已发表的国内外中成药药物经济学研究进行系统评价及质量评估,旨在发现相关问题并提出改进意见。方法计算机检索CNKI、WanFang Data、VIP和PubMed数据库,搜集整理国内外中成药药物经济学相关研究,检索时限均为建库至2022年5月20日。从标题、年份、作者、期刊、研究角度、研究类型、疾病领域、研究对象、研究设计类型、研究方法、应用模型、模型校准、敏感性分析、成本测算、有效性指标、不良反应比较等多方面对中成药药物经济学研究进行系统评价,采用卫生经济学评价报告标准共识2022(CHEERS 2022)和卫生经济研究质量评价表(QHES)对报告质量和方法学质量进行评估。结果共纳入249篇研究,包括中文文章247篇和英文文章2篇。第一篇中成药药物经济学的文献发表于2000年;研究所涉及病种占ICD-11疾病领域的59.26%;报告了研究角度的文章占研究总量的16.87%;对研究类型进行说明的研究占比为32.4%;研究方法主要为成本-效果分析的研究占比为86.75%;成本主要为直接医疗成本的研究占比为89.56%;有效性指标主要为总有效率的研究占比为78.31%。研究质量评估结果显示,CHEERS 2022平均符合率为43.58%,QHES平均评分为56.7分。结论现有的中成药药物经济学研究中有相当一部分存在研究方法、内容缺失或者不规范等问题,应规范化中成药药物经济学研究的设计和报告,提高研究质量。
Objective This study aims to conduct a systematic review and quality assessment of published domestic and foreign studies on the pharmacoeconomics of Chinese patent medicines,with the goal of identifying relevant issues and proposing improvement suggestions.Methods The methods used in this study involved systematic searches of the CNKI,WanFang Data,VIP,and PubMed databases for domestic and foreign studies related to the pharmacoeconomics of Chinese patent medicines,with a search deadline of May 20,2022.The studies were evaluated systematically based on various aspects such as title,year,author,journal,research perspective,research type,disease area,research object,research design type,research method,application model,model calibration,sensitivity analysis,cost calculation,effectiveness indicators,and adverse reaction comparison.The evaluation of report quality and methodological quality was conducted using the consolidated health economic evaluation reporting standards 2022(CHEERS 2022)and the quality of health economic studies(QHES)tools,respectively.Results This study included a total of 249 articles,including 247 in Chinese and 2 in English.The first article on the pharmacoeconomics of Chinese patent medicine was published in 2000.The diseases studied covered 59.26%of the ICD-11 disease areas.Articles reporting on the research perspective accounted for 16.87%of the total number of studies,while 32.4%of studies provided an explanation of the research type.The main method used was cost-effectiveness analysis,accounting for 86.75%of the studies,and the main cost component was direct medical costs,accounting for 89.56%.The primary effectiveness indicator was the overall effective rate,accounting for 78.31%of the studies.The average compliance rate with the CHEERS 2022 standard was 43.58%,and the average QHES score was 56.7.Conclusion A considerable part of the existing research on the pharmacoeconomics of traditional Chinese medicine(TCM)suffers from problems such as the lack of research methods or non-standardized methods.Therefore,the relevant research abilities of researchers who conduct TCM pharmacoeconomic research need to be improved.
作者
杨一玖
张海力
梁宁
宋填
曹文杰
李慧珍
宗星煜
陈雅馨
王巍力
王丁熠
胡紫腾
王燕平
韩晟
史楠楠
YANG Yijiu;ZHANG Haili;LIANG Ning;SONG Tian;CAO Wenjie;LI Huizhen;ZONG Xingyu;CHEN Yaxin;WANG Weili;WANG Dingyi;HU Ziteng;WANG Yanping;HAN Sheng;SHI Nannan(Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,P.R.China;International Research Center for Medicinal Administration,Peking University,Beijing 100191,P.R.China;School of Pharmacy,Peking University,Beijing 100191,P.R.China)
出处
《中国循证医学杂志》
CSCD
北大核心
2023年第9期1053-1059,共7页
Chinese Journal of Evidence-based Medicine
基金
国家自然科学基金项目(编号:82174532)
中国中医科学院科技创新工程项目(编号:CI2021A00702)
中国中医科学院中央级公益性科研院所基本科研业务费自主选题(编号:ZZ14-FL-005)
国家中医药管理局青年岐黄学者项目。
关键词
中成药
药物经济学
系统评价
质量评估
Chinese patent medicine
Pharmacoeconomics
Systematic review
Quality assessment
